3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

3M-011 (0-100 μg/mL; 24 hours; B16-F10 melanoma cells) treatment decreases B16-F10 melanoma cell counts[1]. In humans, 3M-011 activates TLR7 and TLR8, whereas in mice, it activates only TLR7[1]. NF-κB reporter is integrated into HEK-293 cells transfected with human or mouse TLR7 or TLR8, resulting in dose-dependent NF-κB-controlled luciferase activity, except with mouse TLR8. 3M-011 enhances natural killer (NK) cell cytotoxicity[1].

The treatment of scid/NOD mice bearing B16-F10 cells with 3M-011 (1 mg/kg; intravenous injection; every other day for six doses; female scid/NOD mice) demonstrates antitumor effects and induces a dose-dependent increase in serum concentrations of TNF-α and IFN-α/β. Additionally, wild-type C57BL/6 mice are subcutaneously injected with varying doses of 3M-011 (0.01 mg/kg, 0.1 mg/kg, 1 mg/kg, or 10 mg/kg)[1].